top of page
Asha's Focus: Devasting Neurological Conditions
Neurodegeneration
Neuro-oncology
Neuromuscular
Neurovascular
& Stroke
Asha Therapeutics Internal Programs
Asha Research Labs Partnered Projects
Novel Design Preclinical Optimization
APOE4
LysoPRISM™ Compound
Tau
AcetylPRISM™ Compound
Sigma Factor
GenePRISM™ Antibiotic
Undisclosed
Asha Research Labs Partnered Projects
Asha Therapeutics Internal Programs
Asha Research Labs Partnered Projects
ASHA-091
Alzheimer's, Parkinson's
& ALS
ASHA-624
ALS, MS, Glaucoma
Peripheral Neuropathies
ASHA-044
Colorectal Cancer
Hepatocellular Carcinoma
Melanoma
Novel Design Lead Optimization IND-Enabling Clinical Trials
Small Molecule - DRP1 Inhibitor
Intra-molecular Glue - SARM1 Inhibitor
Targeted Protein Degrader - Beta-Catenin
ASHA-197
Pancreatic Cancer
Lung Cancer
Colorectal Cancer
Molecular Glue - Mutant RAS
ASHA-711
Alzheimer's Disease
Lysosomal Degrader - APOE4
Undisclosed
Asha Research Labs
Partnered Asset
Undisclosed
Patients are our priority, designing curative medicines is our mission
Our primary focus is patients suffering from currently incurable life altering diseases. The disruptive PRISM™ Platform is a leading-edge novel physics-based drug design engine that has resulted in a pipeline of clinic-ready assets for the treatment of diseases across multiple clinical areas including neurology, oncology, and infectious disease.
ASHA-091
Alzheimer's, Parkinson's
ALS, Stroke, Post-viral Illness
ASHA-624
ALS, MS, Glaucoma
Peripheral Neuropathies
Novel Design Lead Optimization IND-Enabling Clinical Trials
Target - Mitochondrial DRP1
Target - SARM1
Undisclosed
PRISM™ Novel Design Program
Target - Multiple
Pioneering Breakthrough Therapeutics & Empowering
Hope for Improved Patient
Outcomes
bottom of page